N/A
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A3305894
1988
-
500
KCI등재후보
학술저널
452-459(8쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
Since the presence of concomitant hepatitis B surface antigen and anti-body has been reported by Koziol et al, in blood donors the concomitancy has been evaluated by means of subtyping of HBsAg and anti-HBs. The subtype of HBsAg and/or anti-HBs was es...
Since the presence of concomitant hepatitis B surface antigen and anti-body has been reported by Koziol et al, in blood donors the concomitancy has been evaluated by means of subtyping of HBsAg and anti-HBs. The subtype of HBsAg and/or anti-HBs was essayed through radioimmunoassay in 46 patients with concomitant hepatitis B surface antigen and antibody, and 19 patients with HBsAg positive but anti-HBs negative. The following results were obtained. 1) The concomitant HBsAg/anti-HBs positivity was seen in 18,9% of HBsAg positive patients. 2) In the most of concomitant cases (16.0%), the pattern was indicative of HBsAg/ad in the presence anti-ay, non-neutralized antibody. 3) The ad subtype of HBsAg in control group and concomitant group were 94.7%, 84.8%, respectively. And among 46 cases of concomitant group, the subtype of anti-HBs was anti-ay in 39 (84.7%). 4) No significant correlation was noted between the subtypes found and severity of the clinical disease. 5) In concomitant subjects. the mean S/N ratio of HBsAg was 73.9±25.3 and positive rate of HBeAg was 71,7%. In patients with HBsAg(+)/anti-HBs (-), the mean S/N ratio of HBsAg as 79.7±10.5 and positive rate of HBsAg was 78.9%, and there was no significant statistical significance between concomitant group and control group. In conclusion, the majority of subtype of HBsAg was ad in Korea and the most common pattern of subtypes in concomitant cases was ad in HBsAg and anti-ay in anti-HBs. In concomitant cases, there were various patterns of clinical entity and serologic profiles and it may provide a clue to lack of complete protection against HBV in some persons after earlier HBV infection.